FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (£59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.
Biologics developers backed by Medicxi Ventures’ new €210m ($229m) fund will use Lonza for contract manufacturing under an existing deal with Index Ventures.